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Recent studies on T cell immunology have been instrumental in developing therapies to overcome cancer immune escape, and 
immune checkpoint inhibitors have emerged as one of the most promising therapeutic tools in advanced cancer patients. 
Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies that modulate the effects of immune checkpoints. These in-
clude cytotoxic T lymphocyte antigen 4 and programmed cell death protein 1, which are co-inhibitory signals responsible for 
immune suppression. Despite their clinical benefits, ICPIs behave as general immune activators, exerting to several toxic effects 
called immune-related adverse events attributed to organ-specific inflammation. Here, we review ICPI toxicities, highlighting 
the importance of their early identification and proper management. (J Rheum Dis 2019;26:221-234)
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INTRODUCTION
Concept of cancer immunotherapy 
Cancer immunotherapy is a cancer therapeutic para-
digm that has been rapidly changing in recent years, espe-
cially for metastatic disease treatment. Immunotherapy 
encompasses the development and use of new com-
pounds to harness the patient’s own immune system to 
fight cancer. The immune system’s main function is not 
to fight cancer because cancer is a “recent” event. However, 
the concept of cancer immunotherapy starts from the fol-
lowing premise. Cancer arises from our own cells; the 
cells are not “foreign” like an infection. However, cancers 
arise because of gene mutations that may result in the ex-
pression of abnormal proteins on cancer cells. The abnor-
mal cancer cell proteins could be recognized by the im-
mune system. In such a case, does the immune system 
“recognize” cancer and destroy cancer cells? 
The immune system exerts a strong selective pressure 
during cancer progression, leading to immune tumor 
editing. Cancer cells often co-opt for immune suppressive 
and tolerance mechanisms to avoid immune destruction. 
The emergence of cancer immunotherapy is supported by 
accumulating knowledge about immunology in the carci-
nogenic process, which is to be summarized as follows. 
During the early phase of carcinogenesis, genetic and ge-
nomic alterations or aberrations drive the advent of tu-
mor-associated antigens (TAAs) or determinants, which 
are normally recognized and removed by the host im-
mune system. However, the accumulation of TAAs and 
immune-escaped cancer cells leads to immune evasion or 
disruption. Thus, cancer cells can evade immunosurveillance 
and progress through mechanisms like (1) loss of major 
histocompatibility complex or co-stimulatory molecules 
(including transforming growth factor and interleukin- 
10), (2) ineffective presentation of tumor antigens, (3) 
release of immunosuppressive factors, (4) T cell ex-
haustions (anergy), and (5) recruitment of immune sup-
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pressive cells (myeloid derived suppressor cells, tumor 
associated macrophage, neutrophil, regulatory T cell). In 
this review, we particularly focus on T cell checkpoint dys-
regulation and the suppression of antitumor immune re-
sponse [1,2].
Definition of immune checkpoint inhibitors (ICPIs)
We already know that cancer cells can hijack immune 
checkpoints that act as “brakes” to escape immune 
detection. We hypothesize that we can make drugs, ICPIs, 
to “release the brake” and remove inhibitory T-cell activa-
tion signals that empower tumor-reactive T cells to over-
come regulatory mechanisms and mount an effective an-
titumor response [3,4]. The immune checkpoint block-
ade suppresses T cell-negative co-stimulation to unleash 
antitumor T cell responses that recognize TAAs [5].
Importantly, the development of immune checkpoint 
blockade therapies was predicated by basic research that 
identified key regulatory mechanisms in T-cell activation. 
However, much remains to be elucidated, and further in-
sight would be essential to rationally develop im-
munotherapeutic approaches. To summarize, immune 
checkpoints represent immunological brakes that block 
activating effects. They are crucial for self-tolerance, 
which prevents the immune system from attacking cells 
indiscriminately. 
For the present, two molecules–cytotoxic T-lymphocyte 
antigen 4 (CTLA-4) and programmed cell death protein 1 
(PD-1) or its ligand (PD-L1)–are active targets for ther-
apeutic interventions to augment immunologic reaction 
against malignant cells. CTLA-4 (CD152) is expressed on 
the surface of CD4+ and CD8+ lymphocytes. It trans-
mits an inhibitory signal to T cells by competing with 
co-stimulatory receptor CD28 for its B7 ligands, CD80 
(B7-1) and CD86 (B7-2), which are present on anti-
gen-presenting cells [6]. CTLA-4 binds CD80 and CD86 
with greater affinity and avidity than CD28, enabling it to 
outcompete CD28 for its ligands. Blocking CTLA-4 using 
therapeutic CTLA-4 monoclonal antibodies like ipilimu-
mab and tremelimumab releases CD28, which binds to B7 
ligands to produce a stimulatory signal.
Another target, PD-1 (CD279), is a cell surface protein 
on T cells, B cells, and natural killer cells. Interacting with 
its ligands, PD-1 promotes programmed cell death of an-
tigen-specific T-cells in lymph nodes. It also inhibits 
apoptosis in Treg cells. PD-L1 and PD-L2 promotes T cell 
exhaustion, which prevents cytotoxicity in cancer cells 
[5]. Its ligand, PD-L1 is expressed in a variety of cells in-
cluding cancer cells. High expression of PD-L1 is corre-
lated with poor prognosis in several type of cancers. The 
PD-1:PD-L1 interaction results in T cell suppression 
(anergy, exhaustion, and death). Overexpression of 
PD-L1 by cancer cells activates the PD-1 pathway, which 
subsequently blocks the immune response by down-reg-
ulating T cell effector functions [7]. Therapeutic anti-
bodies against PD-1, pembrolizumab and nivolumab, and 
those against PD-L1, durvalumab, avelumab, and atezoli-
zumab, all block immune checkpoints from binding to 
their ligands. This releases the brakes and unleashes T 
cells. These antibodies–called ICPIs–have recently re-
shaped the therapeutic landscape in a variety of cancers 
including malignant melanoma, non-small cell lung can-
cer, colorectal cancer, and urothelial cancers [2]. Moreover, 
different conventional cancer treatment modalities–che-
motherapy, radiotherapy, and anti-angiogenic therapy–
are being tested in combination with ICPIs to achieve syn-
ergistic effects and overcome ICPI-related resistance. 
Definition of immune-related adverse events (irAEs)
In contrast to conventional chemotherapy and targeted 
therapies, ICPIs can cause inflammatory side effects by 
promoting the activity of the immune system and causing 
a unique constellation of inflammatory toxicities that are 
known as irAEs. irAEs may warrant the cessation of ther-
apy or the administration of immunosuppressive agents. 
irAEs most commonly involve the gastrointestinal (GI) 
tract, endocrine glands, skin, and liver. Less often, the 
central nervous system and cardiovascular, pulmonary, 
musculoskeletal, and hematologic systems are also 
involved. The incidence of irAEs of any grade is reported 
to range from 15% to 90% in single agent trials. The rate 
of severe irAEs requiring medical treatment and with-
drawal of immunotherapy is approximate 0.5%∼13%. 
They are sometimes fatal unless appropriately managed 
[8]. 
Here, we review the current literature on appropriate 
steps for patient evaluation with an eye toward the 
prompt diagnosis of irAEs. We also describe strategies for 
optimizing patient outcome with suitable treatments. 
MAIN SUBJECTS
Assessment and general management principles 
for irAEs
1) Timing of irAE occurrence
The major pathophysiology of irAE is the non-specific 
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enhancement of the immune response driven by T-cell ac-
tivation and subsequent inflammation in normal tissues. 
Knowing when suspected irAEs began manifestation is 
sometimes helpful in therapy. Most ipilimumab-related 
irAEs occur during the induction period, (1) cutaneous 
manifestation is the earliest to appear at 2∼3 weeks after 
the first dose of ipilimumab, (2) GI toxicities like enter-
ocolitis and hepatitis present approximately 5∼10 and 12∼
16 weeks after the second and the third dose, respectively, 
(3) endocrinopathy appears from week 9 onwards after 
the fourth dose, (4) immune-mediated pneumonitis is 
documented 8∼14 weeks after treatment initiation, and 
(5) nephritis appears much later after 14∼42 weeks on 
immunotherapy [9]. 
However, similar temporal associations with the appear-
ance of irAEs has not been described for PD-1/PDL-1 
antagonists. Pembrolizumab has a median onset of mod-
erate to severe toxicity around nine weeks compared to 
six weeks with ipilimumab. In a pooled analysis of pa-
tients treated with nivolumab, 54% of whom had been 
treated with ipilimumab, the median onset of skin irAEs 
was 5 weeks, gastrointestinal at 7.3 weeks, hepatic at 7.7 
weeks, pulmonary at 8.9 weeks, endocrine at 10.4 weeks, 
and renal irAEs at 15.1 weeks [9]. Some patients exposed 
to ICPIs develop late-onset irAEs that may occur after 
treatment has been completed.
2) Patient selection and baseline assessment
Patients should be assessed for susceptibility to irAE de-
velopment before treatment. Initial assessment consists 
of the patient/family history, general physical condition, 
underlying autoimmune diseases, baseline laboratory 
tests and radiological exams (mostly computed tomog-
raphy [CT] scans of the chest, abdomen/pelvis and often 
brain magnetic resonance imaging [MRI]). Patients with 
a history of autoimmune disease or who are being actively 
treated for it are at risk for worsening the underlying au-
toimmune disease while on immunotherapy.
The standard system to describe toxicity in clinical trials 
is to assess and grade according to the Common 
Terminology Criteria for Adverse Events (CTCAE), and 
these may also be applied at the bedside. The severity of 
adverse events is graded on a scale from grade 1 to 5 
(1=mild, 2=moderate, 3=severe, 4=life threatening, 
and 5=mortality related to toxicity). While the CTCAE 
provides a useful framework, they may underestimate 
some irAEs like pituitary dysfunction. 
3) Clinical landscape of irAEs
Grade 3/4 toxicities occur in 5%∼22% of patients un-
dergoing ipilimumab therapy [10-12]. The most common 
irAE are dermatological (rash, pruritus) or GI (diarrhea, 
enterocolitis) toxicity. It is noteworthy that ipilimumab 
toxicity is dose-dependent, with toxicity frequency in-
creasing at a 10 mg/kg dose (e.g., adjuvant setting in mel-
anoma). 
In contrast, anti-PD-1 therapies are generally less toxic 
compared to anti-CTLA4 therapy, with grade 3/4 events 
reported in approximately 5%∼11% of patients treated 
with nivolumab and 8%∼14% of patients treated with 
pembrolizumab [13-16]. Nivolumab-related irAEs are 
not dose-dependent; grade 3/4 pembrolizumab toxicities 
are somewhat higher at a dose of 10 mg/kg every 2 weeks 
than 2 mg/kg (U.S. Food and Drug Administration 
[FDA]-approved dose) or 10 mg/kg every 3 weeks [14]. 
The most common irAEs seen in anti-PD-1 therapy in-
volve rash, pruritus, diarrhea, nausea, loss of appetite and 
arthralgia [16,17]. 
Certain irAEs are more common according to cancer 
types. Pneumonitis is more prevalent in lung cancer pa-
tients in whom pre-existing pulmonary inflammation 
(possibly from tobacco, previous lung damage or carci-
nogen exposure) can be implicated. The exclusive devel-
opment of vitiligo is noteworthy in melanoma patients. 
Melanoma patients also have higher rates of colitis due in 
part to greater experience with ipilimumab. Hematologic 
toxicity is more commonly attributed to ICPIs in malig-
nant lymphoma studies, which may represent a reporting 
bias though. Discovering and validating predictive bio-
markers for other irAEs is an area of ongoing research. We 
might unearth novel irAEs as ICPIs become more widely 
used in other malignancies. Briefly, anti-PD-L1 anti-
bodies do not seem to cause as many high-grade irAEs 
compared to anti-CTLA4 antibodies, but this is not con-
clusive due to the small number of studies.
4) Management strategy for irAEs
It is imperative for oncology personnel to be well-versed 
in the heterogeneous presentations of irAEs and to do 
comprehensive assessment for patients. Patient and care-
giver education about the significance of early detection 
and prompt reporting is important for timely recognition 
and management. Education should include the dis-
cussion of key points about irAEs, criteria for early inter-
vention, and confirmation of the patient’s ability to ver-
balize symptoms. It should emphasize that symptoms 
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Table 1. General management guideline of immune-related adverse events
Severity 
CTCAE 
grade
Type of 
patient care
Use of 
steroid
Use of additional 
immunosuppressive 
agents
Continuation of 
next cycle 
immunotherapy
Other 
medication
1 Outpatient Generally, not necessary Not recommended Continue Not recommended
2 Outpatient Topical steroids or oral 
steroids: Prednisone 
0.5∼1 mg/kg/d
Not recommended Suspend temporarily: 
outside skin or 
endocrine disorders, 
where immunotherapy 
can be maintained
Not recommended
3∼4 Consider 
hospitalization 
according to 
the specific 
case
IV or oral steroids; 
prednisone or 
methylprednisolone 
1∼2 mg/kg/d for 
48∼72 hours, then 
reduce to 1 mg/kg/d; 
course of generally 
2∼4 weeks; steroids 
must be reduced 
gradually over a period 
of at least 1 month 
Considered 
administration of 
infliximab (5 mg/Kg) 
and eventually repeat 
after 14 days; Consider
mycophenolate 
mofetil (500 mg every 
12 h)
Skipping a dose of 
immunotherapy or 
discontinuing the 
immunotherapy can be 
considered, depending 
on the benefit/risk ratio 
of each given situation; 
If grade 4 toxicity occurs, 
discontinue 
permanently
If a dose equivalent to 
20 mg of prednisone 
is administered for 
over 4 weeks, 
consider prophylaxis 
for pneumocystis 
infections with 
trimethoprim/ 
sulfamethoxazole 
(80+40 mg/d or 
160/800 mg TIW)
CTCAE: common terminology criteria for adverse events, TIW: 3 times a week.
may be intermittent and can even occur weeks to months 
after completion of the treatment. Consultation with oth-
er specialties is also advisable. General guidelines for the 
management of irAEs using ipilimumab are described in 
the FDA Risk Evaluation and Management Strategies 
[18]. A similar approach is expected to apply to PD-1 
inhibitors. Recently, Clinical Practice Guidelines were de-
veloped in accordance with the European Society for 
Medical Oncology (ESMO) standard operating proce-
dures for Clinical Practice Guidelines development 
[19,20].
As a rule, the management of severe irAEs requires im-
mediate interruption of the drug and initiation of 
corticosteroids. For patients with grade 2 toxicities, ICPIs 
should be withheld and not resumed until toxicity is 
grade 1 or lower. If symptoms do not resolve within a 
week, corticosteroids (prednisone 0.5 mg/kg/day or 
equivalent) must be initiated. On the other hand, for pa-
tients experiencing grade 3/4 irAEs, the drug should be 
permanently discontinued and high doses of cortico-
steroids (prednisone 1 to 2 mg/kg/day or equivalent) 
should be started. When the symptoms subside to grade 
1 or lower, steroids should be gradually tapered off over a 
month. However, in intractable cases, administration of 
infliximab (for GI toxicity) or mycophenolate (for hep-
atotoxicity) should be considered [21]. Following is sum-
mary of several general rules that are widely accepted irre-
spective of the affected organs, and a general irAE man-
agement guideline is summarized in Table 1.
• For grade 2 irAEs: ICPI should be interrupted and re-
sumed when symptoms or laboratory values decrease to 
grade 1 or lower. Glucocorticoids (prednisone 0.5∼1 
mg/kg/day or equivalent) should be considered if symp-
toms persist for more than 1 week.
• For grade 3/4 irAEs: High doses of glucocorticoids 
(prednisone 1∼2 mg/kg/day or equivalent) should be 
started. The glucocorticoids should be tapered off gradu-
ally when symptoms subside to grade 1 or lower. Patients 
on 20 mg or equivalent prednisone doses for at least 4 
weeks should also consider prophylactic management 
against Pneumocystis jirovecii.
• If symptoms continue for more than 3 days on intra-
venous (IV) glucocorticoids, alternative immunosuppressive 
agents should be considered (infliximab 5 mg/kg; myco-
phenolate mofetil for hepatitis). Infliximab 5 mg/kg 
should be repeated after 2 weeks for persistent 
symptoms.
• For grade 4 irAEs: ICPIs should be discontinued per-
manently (except in endocrinopathies when controlled 
by proper hormone replacement). Therapy can be re-
sumed in selected patients with grade 3 toxicities (see be-
low organ-specific toxicities section).
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ICPIs should also be stopped permanently in the follow-
ing circumstances:
• Grade 2 reactions lasting for 6 weeks or more. 
However, anti-PD-1/PD-L1 therapies can be continued in 
endocrinopathies when controlled by proper hormone 
replacement.
• Inability to reduce glucocorticoid dose to 7.5 mg pre-
dnisone or daily equivalent for patients treated with an-
ti-CTLA-4 antibodies and less than 10 mg/day within 12 
weeks for anti-PD-1 therapy.
• Grade 2∼4 ocular toxicities not improving to grade 1 
within 2 weeks after treatment with topical immuno-
suppression or requiring systemic treatment.
The mechanisms of action of commonly used im-
munomodulatory medications are summarized as fol-
lows, and communication with other specialists is highly 
recommended to combine expertise on non-steroid im-
munosuppression strategies. 
(1) Steroids have various effects on T cells, B cells and 
macrophages, which include inhibition of cytokine or in-
terleukin production, inhibition of neutrophil apoptosis, 
and reduced macrophage function.
(2) Infleximab is a monoclonal antibody that prevents 
tumor necrosis factor alpha (TNF-α) from binding to its 
receptors.
(3) Mycophenylate mofetil (MMF) suppresses inosine 
monophosphate dehydrogenase, an enzyme involved in nu-
cleotide production, particularly in activated lymphocytes. 
(4) Tacrolimus and cyclosporine are calcineurin in-
hibitors that limit transcription of interleukin-2, which is 
involved in T cell proliferation. 
The association between irAEs and the efficacy of ICPIs 
is still controversial, and a recent retrospective analysis 
reported similar overall survival in patients who received 
immunosuppression. Combination immunotherapy has 
only been approved for metastatic melanoma. The onset 
of G3/4 toxicities for either monotherapy with nivolumab 
or combination immunotherapy differs, since irAEs may 
develop earlier in combination therapy and may start over 
a prolonged period of time.
Organ-specific adverse events and management
1) Cutaneous toxicity
Cutaneous toxicity is the most common and the earliest 
developing irAE, and it shows myriad clinical manifes-
tations, including maculopapular, follicular, pustular, ve-
sicular and acneiform eruptions. These were earlier cate-
gorized by Curry et al. [22] into 4 groups, according to 
their histomorphology: (1) inflammatory, (2) im-
munobullous, (3) alterations of epidermal keratinocytes 
and (4) alterations of epidermal melanocytes. Approximately 
half of patients treated with ipilimumab will experience 
rash or pruritus, and rashes are often mild in severity and 
present after the first or second dose [23]. Skin biopsy 
usually reveals perivascular lymphocytic infiltrates ex-
tending deep into the dermis [24]. Rare cases of Steven- 
Johnson syndrome have also been reported [10,25]. 
Combination immunotherapy was associated with a 
higher rate of severe skin toxicity (2.9%) [26]. 
Regarding the maculopapular rash, the most frequent 
cutaneous toxicity, CTCAE classification proposes:
• Grade 1: macules/papules covering less than 10% the 
body surface area (BSA) with or without symptoms (e.g., 
pruritus, burning, tightness);
• Grade 2: macules/papules covering 10%∼30% BSA 
with or without symptoms (like pruritus, burning, tight-
ness); limiting instrumental activities of daily living 
(ADL);
• Grade 3: macules/papules covering more than 30% 
BSA with or without associated symptoms; limiting 
self-care ADL; 
• Grade 4: papulopustular rash associated with life- 
threatening superinfection; Stevens–Johnson syndrome, 
toxic epidermal necrolysis, and bullous dermatitis cover-
ing more than 30% of BSA and requiring intensive care 
unit (ICU) admission.
Dermatological toxicity is also observed with anti-PD1 
therapy (30%∼40%) [27]. Interestingly, skin toxicity 
mainly develops in patients with melanoma. For example, 
vitiligo was reported in approximately 10% of patients 
[13,26], but it was not described in lung or renal cell car-
cinoma studies [28,29]. Notably, vitiligo was also shown 
to be predictive of a durable response [30]. Treatment 
management for skin toxicity can be summarized as 
follows. 
• Grade 1/2 toxicity: ICPIs should be continued for at 
least 1 week. Treatment with topical emollients, antihist-
amines in the case of pruritus or topical mild strength cor-
ticosteroid creams should be started. ICPI should be re-
initiated when at or below G1.
• Grade 3 toxicity: ICPI should be interrupted and treat-
ment with topical emollients, antihistamines, and high 
strength corticosteroid creams should be start immediately.
• Grade 4 toxicity: ICPI should be discontinued perma-
nently, the patient should be hospitalized and dermato-
logical consultation for skin biopsy should be scheduled. 
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IV corticosteroids (1∼2 mg/kg [methyl]prednisone) 
should be started, and steroids should be tapered off over 
1 month after resolution of AE to grade 1 [11,25].
GI toxicity: diarrhea and enterocolitis
Diarrhea is a common clinical manifestation in ICPI 
treatment. Diarrhea is clinically different from enter-
ocolitis, which involves abdominal pain and radiological 
and laboratory signs of colonic inflammation. Diarrhea 
most commonly arise within 6 weeks on ipilimumab or 
nivolumab and as late as 6 months on pembrolizumab 
[25,31]. Both conditions should be excluded from enter-
ocolitis caused by Clostiridium difficile and other 
pathogens. 
In a phase III ipilimumab trial for melanoma, diarrhea of 
any grade was reported in 30% of patients. Grade 3/4 tox-
icity, defined as 7 or more stools above baseline, fever, 
ileus or peritoneal signs, was observed in 10% and was 
dose-dependent (10% at a 10 mg/kg dose vs. 1% at a 3 
mg/kg dose) [10]. Meanwhile, enterocolitis appears to be 
less common, with an incidence of approximately 5% 
[10]. Endoscopic findings revealed mucosal edema with 
biopsies demonstrating neutrophilic, lymphocytic or 
mixed neutrophilic-lymphocytic infiltrates [32]. CT scan 
findings associated with ICPI-induced colitis included 
mesenteric engorgement and bowel wall thickening [33]. 
Diarrhea or colitis was less frequent with PD-1 blockers 
compared to CTLA-4 blockers, and G3/4 toxicity was 
seen in about 1% to 2% of cases [13,16,34]. Interestingly, 
patients who developed significant diarrhea and enter-
ocolitis during CTLA-4 blockade were subsequently been 
treated with PD-1 antibodies without experiencing com-
plications [35].
Management starts with maintaining oral hydration. In 
patients with mild diarrhea, administration of ICPIs 
should be continued without starting corticosteroids. 
Low residual diet and anti-motility agents like loper-
amide can help. Colonoscopy is reserved for patients with 
G2 or higher diarrhea or in cases where diagnosis is 
unclear. If G3/4 enterocolitis develops, ipilimumab 
should be permanently discontinued and high dose IV 
corticosteroids should be started [23,36]. If symptoms do 
not resolve in 3 days, treatment with 5 mg/kg anti-TNF 
antibody infliximab once every two weeks is recom-
mended [37]. In infliximab-refractory cases, mycopheno-
late mofetil can be used. In rare cases, enterocolitis can re-
sult in perforation and require colostomy. Treatment 
management can be summarized as follows. 
• Grade 1 toxicity, defined as fewer than 4 liquid stools 
per day over baseline; ICPI can be continued. High fi-
ber/lactose diet should be avoided. Treatment with anti-
diarrheal medication, like loperamide, should be prescribed. 
• Grade 2 toxicity, defined as 4 to 6 liquid stools per day 
over baseline or abdominal pain or blood in stool or nau-
sea or nocturnal episodes, ICPI should be interrupted and 
the patient should start with corticosteroids depending 
on the severity and other symptoms (either budesonide 
or oral corticosteroids 1 mg/kg). If the patient shows no 
improvement within 3 to 5 days, colonoscopy should be 
done and, in the case of colitis, infliximab 5 mg/kg should 
be administered.
• Grade 3/4 toxicity, defined as 7 or more liquid stools 
per day, is life-threatening. It requires hospitalization and 
isolation until the infection is treated. ICPI should be per-
manently discontinued and (methyl)prednisone 2 mg/kg 
IV should be initiated. Patients who respond to IV corti-
costeroids within 3 to 5 days should be switched to the or-
al formula, which should be tapered off over 8 to 12 
weeks. Patients who do not respond to corticosteroids 
within 3 to 5 days should be transitioned to infliximab, 
unless it is contraindicated.
GI toxicity: hepatotoxicity
Hepatotoxicity has been observed with both an-
ti-CTLA-4 and anti-PD-1 inhibitors. It occurs within 8∼
12 weeks after treatment initiation and generally mani-
fests as elevation of levels of the liver enzymes aspartate 
aminotransferase (AST) and alanine aminotransferase 
(ALT). Elevation of total bilirubin level is a rare con-
sequence of prolonged periods of elevated liver enzyme 
levels [11]. The phase III melanoma trial of ipilimumab 
reported grade 2 hepatotoxicity in 2.5% in patients and 
the incidence of grade 3 to 5 events reached 2% [10]. In 
the large phase I trial of anti-PD-1 blockers, grade 1/2 liv-
er dysfunction was noted in approximately 5% of pa-
tients, and grade 3∼5 events were rare (1%) [16]. The in-
cidence of hepatotoxicity is higher with the combination 
of ipilimumab and nivolumab, with grade 3/4 events up 
to 20% [26]. Liver biopsy may be considered to assist dif-
ferential diagnosis. Lobular hepatitis indistinguishable 
from autoimmune hepatitis is commonly reported, and 
most cases are panlobular but inflammation may be con-
fined to zone 3. Additional sinusoidal histiocytosis and 
central vein endothelitis may help identify ipilimu-
mab-associated inflammation [26].
In the clinic, liver enzymes should be monitored regu-
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larly prior to each dose of ICPIs. Management of hep-
atotoxicity starts by ruling out other liver injury etiol-
ogies, including concomitant medications, alcohol con-
sumption, and combined viral hepatitis. Radiological 
studies should be performed to exclude metastatic 
disease. In the case of immune-related hepatitis, CT scan 
can show surface nodularity, intrahepatic biliary dilata-
tion, varices, and ascites. 
Treatment with systemic corticosteroids should not be 
delayed [25]. As immune-related hepatitis may persist, a 
minimum of a three-week treatment with subsequent ta-
pering of the dose is required. For grade 2 hepatotoxicity, 
defined as AST or ALT values 2.5 to 5 times the upper lim-
it of normal (ULN) and total bilirubin values between 1.5 
to 3 ULN, treatment with ICPIs should be withheld. 
Steroid therapy should continue until toxicity resolves to 
grade 0 or 1. For grade 3/4 immune-related hepatitis 
(AST/ALT values above 5 times the ULN or total bilirubin 
level above 3 times ULN) the drug should be permanently 
discontinued and liver biopsy could be considered. 
Hospitalization is required if liver enzyme levels are 
above 8 times ULN. In rare cases of corticosteroid re-
fractory hepatitis, mycophenolate mofetil (500 mg every 
12 hours) should be given [11,25]. Infliximab should not 
be administered, since it carries a risk of hepatotoxicity.
• Grade 2 hepatitis: ICPI should be withheld and 
AST/ALT levels should be closely monitored (1∼2 
times/week). If there is no improvement in a week, treat-
ment with (methyl)prednisone (0.5∼1 mg/kg) should 
be started. This should be tapered off over several weeks 
under close monitoring of AST/ALT and bilirubin levels.
• Grade 3 hepatitis: ICPI should be discontinued and 
treatment with (methyl)prednisone 1∼2 mg/kg should 
be immediately started. If there is no improvement in 2 to 
3 days, MMF (1,000 mg 3x daily) should be added. 
Immunosuppression should be tapered off over 4 to 6 
weeks under close monitoring of AST/ALT and bilirubin 
levels.
• Grade 4 hepatitis: ICPI should be permanently dis-
continued, hospitalization and initiation of (methyl)pre-
dnisone 2 mg/kg IV is needed. MMF should be added if no 
improvement is observed within 2 to 3 days. A hepatol-
ogy specialist should be consulted if no improvement is 
seen under double immunosuppression. Other im-
munosuppressive drugs to consider are anti-thymocyte 
globulin and tacrolimus. Sometimes the patient should 
be referred to experienced centers. Treatment should be 
tapered off over 6 weeks under close liver function 
monitoring.
Endocrinopathies
Immunotherapy has been causatively associated with 
several endocrinopathies, including hypophysitis, hypo-
pituitarism, adrenal insufficiency, and hypothyroidism. 
The median onset of endocrinopathy is about 7 weeks for 
ipilimumab and 10 weeks for nivolumab [11,38], and 
clinically significant endocrinopathies typically occur in 
less than 5% of patients on ipilimumab. For anti-PD-1 
therapies, grade 3/4 events are rarer (approximately 1%) 
[39,40].
1) Hypophysitis
Hypophysitis, an inflammation of the anterior lobe of 
the pituitary gland, has been associated with ICPIs in pa-
tients with various malignancies. Large differences (0%∼
25%) in the incidence of ipilimumab-induced hypo-
physitis have been reported in different trials [41]. In the 
phase III trial of ipilimumab, severe hypophysitis was re-
ported in 1.8% of patients [10]. On the other hand, trem-
elimumab has been much less frequently shown to be re-
lated to hypophysitis (0.5%∼4%) [42]. Similarly, hypo-
physitis is a rare event with anti-PD-1 antibodies [34,43]. 
The median time to onset is approximately 2 to 4 months 
after treatment initiation, but delayed presentations can 
occur [44,45]. 
The pathophysiology of anti-CTLA4-induced hypo-
physitis remains unclear. In a mouse model, researchers 
noted low-level ectopic CTLA4 RNA and protein ex-
pression on thyrotropin and prolactin secreting cells of 
the pituitary gland [32]. Anti-CTLA4 treatment could 
lead to mononuclear cell infiltration in the pituitary 
gland, anti-pituitary antibodies and activation of the com-
plement cascade in these animals, causing inflammation 
of the gland like what was observed in full-blown hypo-
physitis patients [46].
Hypophysitis presents with non-specific symptoms like 
headache, fatigue, and visual disturbances. A swollen or 
enlarged pituitary gland may be visible in brain MRIs 
[47]. Diagnosis is based on low pituitary hormone levels 
(adrenocorticotropic hormone [ACTH], follicle stimulat-
ing hormone, thyroid-stimulating hormone [TSH], lutei-
nizing hormone and growth hormone), and differential 
diagnosis includes primary hypothyroidism (low thyro-
xine, high TSH) and primary adrenal insufficiency (low 
cortisol). 
In grade 1 hypophysitis, defined as asymptomatic or 
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mild symptoms, only clinical or diagnostic observation is 
recommended. In any grade 2 or higher hypophysitis 
which limits self-care ADL (headache, fatigue, sepsis, se-
vere ataxia), ICPI should be interrupted and high-dose 
corticosteroids should be started (prednisone 1 mg/kg 
daily). Permanent discontinuation of the drug is recom-
mended for grade 3/4 toxicities. Endocrinology con-
sultation and long-term supplementation of affected hor-
mones due to secondary hypothyroidism and hypoa-
drenalism is necessary [25]. Long-term supplementation 
of affected hormones is often required, including secon-
dary hypothyroidism requiring levothyroxine replace-
ment or secondary hypoadrenalism requiring replace-
ment hydrocortisone. In most cases, the immune check-
point inhibition can be continued. Long-term HRT is re-
quired in most patients.
2) Thyroid gland dysfunction
Both hyper- and hypothyroidism have been reported, 
but hypothyroid disorders are more common than hyper-
thyroidism [25]. Still, little is known about the patho-
genesis of thyroid disorders following ICPIs. It is thought 
to be mediated by T cells rather than B cell autoimmunity. 
Hypothyroidism is more common with anti-PD-1 thera-
pies than with ipilimumab 3 mg/kg, but a higher in-
cidence can be seen at high doses (10 mg/kg) [26, 
34,43,48]. 
Hypothyroidism is usually subclinical; hormone re-
placement therapy with levothyroxine can be initiated 
and ICPI treatment can be continued without interruption. 
If concurrent hypophysitis is suspected (low TSH, low 
T4), treatment should not be solely based on TSH mea-
surement. Instead, free thyroxine and T3 levels should al-
so be considered [39]. On the other hand, hyper-
thyroidism is less common and might be a result of tran-
sient thyroiditis preceding hypothyroidism or TSH-re-
ceptor antibodies and Grave’s disease [38]. Persistent hy-
perthyroidism should be treated as primary hyper-
thyroidism. 
According to the ESMO guidelines, substitution with 
thyroid hormone should be considered in the case of fa-
tigue or other complaints that could be attributed to hy-
pothyroidism even with subclinical hypothyroidism. In 
symptomatic patients, especially in the case of hyper-
thyroidism, treatment with beta-blockers should be start-
ed (propranolol or atenolol). Rarely, carbimazole or ste-
roids are used. In those cases, treatment with ICPIs 
should be interrupted until symptom recovery. Hormone 
replacement therapy is usually long-lasting [19].
3) Adrenal insufficiency
Primary adrenal insufficiency was reported in 1.5%∼
2% of patients [39]. It should be distinguished from hy-
pophysitis based on measurement of ACTH levels. Acute 
adrenal insufficiency (adrenal crisis) constitutes an emer-
gency manifesting as dehydration, hypotension, hyper-
kalemia, and hyponatremia. Patients suspected to have 
adrenal crisis should be immediately hospitalized with 
prompt initiation of IV corticosteroids [11]. Endocrinology 
consultation is also warranted.
4) Type I diabetes mellitus
Type I diabetes mellitus (DM) can occur with both an-
ti-CTLA-4 and anti-PD-1 blockade at a rate of less than 
approximately 1% [39]. Incidence is doubled with the use 
of combined ipilimumab and nivolumab [26]. Insulin 
treatment is recommended. Finally, cases of low testos-
terone have been reported in patients treated with ipili-
mumab [45]. 
5) General guideline of endocrinopathies
Below is the summary of management principles for en-
docrinopathy according to ESMO guidelines [19]; 
• In symptomatic hyperthyroidism of grade 1/2, ICPI 
should be interrupted and beta-blocker therapy (propranolol 
or atenolol/metoprolol) should be started. ICPI should 
be restarted when asymptomatic.
• In the case of hypothyroidism (rarely higher than 
grade 2), HRT should be started depending on the se-
verity (50∼100 μg/day). The dose should be increased 
until TSH level is normal. In the case of thyroid gland in-
flammation, treatment with 1 mg/kg prednisone should 
be started orally. This should be tapered based on recov-
ery from clinical symptoms. Interruption of ICPI treat-
ment should be considered when symptomatic.
• In the case of hypophysitis (rarely higher than grade 
2), when headache, diplopia or other neurological symp-
toms are present, treatment with (methyl)prednisone 1 
mg/kg should be started orally and taper over 2 to 4 
weeks. Start HRT depending on the affected hormonal ax-
is (levothyroxine, hydrocortisol, testosterone).
• In patients with type I diabetes mellitus grade 3/4 
(ketoacidosis [sub]coma), hospitalization is needed to 
start treatment of newly onset type I DM. The role of cor-
ticosteroids in preventing complete loss of insulin pro-
ducing cells is unknown and not recommended.
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Immune-mediated pneumonitis
Pneumonitis is an uncommon toxicity of ICPIs, but the 
implicated mechanisms are still undetermined. The hy-
pothesis is that dysregulated effector T cells are accumu-
lated in the pulmonary interstitial, leading to an increased 
inflammatory response [49]. It can occur with both an-
ti-CTLA-4 and anti-PD-1 treatment. Ipilimumab- in-
duced pneumonitis has been reported in up to 5% of pa-
tients in monotherapy [13,34]. A combination of nivolu-
mab and ipilimumab results in pneumonitis at a higher 
incidence (5% to 10%, with 2% G3/4) [26]. Pneumonitis 
can occur in 2% to 5% of patients with nivolumab, and 
more commonly in patients with renal cell and lung can-
cer than in patients with melanoma [34,50,51]. 
The most acute form is acute interstitial pneumo-
nitis/diffuse alveolar damage syndrome, which is some-
times life-threatening [52]. Organizing inflammation 
and sarcoidosis-like granulomatosis has been described 
[53-55]. Rarely, pneumonitis worsens despite im-
munosuppression, and may be fatal due to superimposed 
infection or progressive disease. Patients presenting with 
symptoms of upper respiratory infection like coughing or 
shortness of breath should be evaluated using appro-
priate imaging. However, radiological findings of pneu-
monitis are not pathognomonic, and may demonstrate 
ground glass opacities, a cryptogenic organizing pneumo-
nia-like appearance and interstitial pneumonia pattern, 
and characteristics of hypersensitivity pneumonitis. 
Although lung biopsy or bronchoscopy is not usually re-
quired for decision, it may assist in discriminating acute 
infection, or lepidic or lymphangitic spread of lung cancer, 
from a variety of inflammatory changes described above. 
The treatment strategy is summarized according to the 
ESMO guidelines [19];
• Grade 1 pneumonitis: defined as radiographic change 
only and non-symptomatic, delay ICPI treatment, consid-
er steroids (e.g., prednisone 1 mg/kg/day orally [PO] or 
methylprednisolone 1 mg/kg/day IV). To follow-up, re-
assessment should be done after 3 weeks. If it worsens, 
patients should be treat as grade 2 or 3/4.
• Grade 2 pneumonitis: defined as mild-to-moderate 
symptoms (dyspnea, cough, shortness of breath) limiting 
instrumental ADL, ICPI treatment should be delayed and 
hospitalization considered. Symptoms should be moni-
tored daily. Steroids are recommended (prednisone 1∼2 
mg/kg/day PO or methylprednisolone 1∼2 mg/kg/day 
IV). Empiric antibiotics (if suspicious for concurrent in-
fection) should be considered. To follow-up, manage-
ment should be reassessed every 1 to 3 days. If improve-
ment is observed, steroids is tapered and treatment con-
tinued if symptoms resolve completely. If it worsens, the 
condition should be treated as grade 3/4.
• Grade 3/4 pneumonitis: defined as severe symptoms 
limiting self-care ADL, ICPI is discontinued permanently 
and hospitalization is needed, even in ICU if necessary, 
and high-dose (methyl)prednisone 2∼4 mg/kg IV should 
be immediately started. Infliximab should be added, and 
MMF or cyclophosphamide should be added in the case of 
deterioration under steroids. The drugs should be ta-
pered over a period of 4 to 6 weeks. Prophylactic anti-
biotics should be added for opportunistic infections. 
Bronchoscopy with biopsy should be considered. 
Management should be reassessed daily.
Renal toxicity
The prevalence of renal insufficiency was reported to be 
low (0%∼4%) but it has been reported from both an-
ti-CTLA-4 and anti-PD-1 blockers [38]. The highest in-
cidence reported was in the phase II trial with nivolumab 
in non-small-cell lung cancer [56]. The histopathological 
findings of CTLA-4-induced nephrotoxicity include acute 
granulomatous interstitial nephritis and lupus mem-
branous nephropathy [57,58]. In the case of nephritis, 
first rule out other causes of renal failure. Interrupt or 
permanently discontinue ICPI depending on the severity 
of the renal insufficiency. Stop other nephrotoxic drugs. 
Start (methyl)prednisone 1∼2 mg/kg. Consider renal bi-
opsy to confirm diagnosis.
• Grade 1 toxicity: defined as creatinine above 1∼1.5x 
baseline; proteinuria 1+, less than 1.0 g/24 h: monitor re-
nal function, promote hydration and cessation of neph-
rotoxic drugs.
• Grade 2 toxicity: defined as creatinine above 1.5∼
3.0x baseline; proteinuria 2+, 1.0∼3.4 g/24 h: exclude 
non-immune causes, commence prednisolone 0.5∼1 
mg/kg. If it worsens, manage as per grade 3 and dis-
continue ICPI.
• Grade 3/4: defined as creatinine above 3.0x baseline; 
proteinuria at or above 3.5 g/24 h: initiate prednisolone 1∼
2 mg/kg or IV equivalent. Consider renal biopsy. 
Discontinue ICPI.
Neurological toxicity
Neurological AEs were reported to be as rare as 1% 
[43,56]. However, recent analysis involving 9,208 pa-
tients demonstrated a somewhat higher incidence: 3.8% 
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in patients receiving anti-CTLA4, 6.1% in patients receiv-
ing anti-PD-1 agents and 12% in patients with an-
ti-CTLA4 in combination with anti-PD-1 drugs [48]. 
Symptoms are varied; polyneuropathy, facial nerve palsy, 
demyelination, myasthenia gravis, Guillain–Barre syn-
drome, posterior reversible leukoencephalopathy, trans-
verse myelitis, enteric neuropathy, encephalitis and asep-
tic meningitis [59,60]. Depending on the clinical pre-
sentations, a work-up including nerve conduction studies 
and lumbar puncture may assist in diagnosis. Early con-
sultation with a neurologist is warranted. 
In the case of mild neurological AEs, ICPI should be 
withheld and work-up should be performed to define the 
nature of the neurotoxicity. In the case of deterioration or 
severe neurological symptoms, the patient should be ad-
mitted and started on (methyl)prednisone 1∼2 mg/kg 
orally or IV. In the case of Guillain–Barre or myasthe-
nia-like symptoms, adding plasmapheresis or IV im-
munoglobulin should be considered.
Rheumatological or musculoskeletal toxicity
Rheumatologic or musculoskeletal irAEs observed in 
patients treated with ICPIs have been mainly focused on 
arthralgia and myalgia, with a prevalence ranging from 
1% to 43% and from 2% to 20%, respectively [61]. It is 
more common with an anti-PD-1 agent. However, the 
prevalence may have been underestimated because only 
high-grade irAEs were reported in some trials [32]. A pat-
tern associated with inflammatory rheumatological con-
ditions (morning stiffness, synovitis, proximal weak-
ness) may be elicited. In addition, arthritis, seropositive 
rheumatoid arthritis (RA), (poly)myositis, sicca symp-
toms, Sjögren's syndrome, and less commonly (temporal) 
vasculitis, cryoglobulinemic vasculitis and lupus neph-
ritis are also reported [25,56,61,62]. Time to onset of 
rheumatic manifestations varies from weeks to months 
after ICPI initiation. Belkhir et al. [63] suggested there be 
a contrast between irAEs occurring after blockade with 
CTLA-4 (colitis, endocrine disorders, skin rashes) and 
PD-1/PD-L1 (non-specific arthritis, sicca syndrome, RA, 
polymyalgia rheumatica, and other connective tissue dis-
eases). 
ICPI treatment may aggravate pre-existing autoimmune 
rheumatic disease (ARD) in 40%∼50% of cases. The 
most frequent is psoriasis exacerbation, but exacerbation 
or aggravation of other disease-RA, scleroderma, chronic 
cutaneous lupus or systemic lupus erythematosus, vascu-
litis, Sjögren’s syndrome, ankylosing spondylitis, my-
ositis, sarcoidosis-have all been reported [64,65]. 
Moreover, rheumatologic patients seem to have a higher 
proportion of flares compared with patients affected by 
non-rheumatologic autoimmune diseases. 
For treatment, non-steroidal anti-inflammatory drugs  
should be started under ICPI continuation for mild symp-
tom of arthralgia. Sometimes, rheumatic irAEs sponta-
neously disappear. In the case of no improvement, 
low-dose steroids (10∼20 mg prednisone) can be 
considered. For severe or fatal cases, multidisciplinary ex-
pertise of oncologists and rheumatologists is crucial for 
successful management. Treatment with 1 mg/kg pre-
dnisone should be started. Infliximab or another an-
ti-TNF-α inhibitor drug is sometimes required for arthri-
tis improvement. There seem no differences in adverse 
events between patients with active disease and those 
with inactive disease, whereas patients receiving im-
munosuppressive therapy at initiation of ICPI seem to 
have fewer irAEs than those not receiving treatment [65].
Cardiac toxicity
The incidence of cardiac AEs is less than 1%, but a wide 
range of toxicities including myocarditis, pericarditis, ar-
rhythmias, cardiomyopathy, and impaired ventricular 
function have been reported after treatment with ipilimu-
mab, pembrolizumab and nivolumab [25,31,48,59]. 
However, the incidence of cardiac toxicity is higher with 
the combination of ipilimumab and nivolumab (0.27%) 
compared with nivolumab alone (0.06%). Early con-
sultation with a cardiologist is recommended. According 
to the recent ESMO guidelines, when myocarditis is sus-
pected, admit the patient and immediately start high- 
dose (methyl)prednisone (1∼2 mg/kg). In the case of de-
terioration, consider adding another immunosuppressive 
drug (MMF or tacrolimus).
Ocular toxicity
Ocular irAEs are rare (less than 1%) treated with ICPIs. 
The clinical presentation can be one of two types: ocular 
inflammation, like peripheral ulcerative keratitis, uveitis 
and Vogt– Koyanagi–Harada syndrome, orbital in-
flammation, including thyroid-associated orbitopathy 
and idiopathic orbital inflammation (scleritis, myositis, 
neuritis, dacryoadenitis); or retinal and choroidal disease 
(choroidal neovascularization and melanoma-associated 
retinopathy) [25,31,48,59]. 
The treatment of these rare toxicities depends on their 
severity, with topical corticosteroids in the case of epis-
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cleritis and anterior uveitis, and systemic corticosteroids 
in the case of severe ocular inflammation and orbital 
inflammation. Intra-vitreal anti-vascular endothelial 
growth factor is indicated for choroidal neova-
scularization.
Hematological toxicity 
Fatigue is the most commonly reported AE in many of 
the ICPI trials, although rarely at a high grade. It is crucial 
to rule out secondary causes like hypothyroidism and 
hypoadrenalism. If other causes are excluded, short-term 
application of prednisolone (10∼20 mg) may be helpful 
in managing intolerable cases. 
Red cell disorders–hemolytic anemia, red cell aplasia 
and acquired hemophilia A–are all reportedly related to 
ipilimumab [66,67]. Mortality from probable drug-in-
duced neutropenia was reported in one patient on nivolu-
mab [10]. Grade 3 myelodysplasia was also reported in 
one case with Hodgkin’s lymphoma on nivolumab. 
Pembrolizumab has only been associated with low grade 
anemia and neutropenia [5]. ICPI-associated sarcoidosis 
has been reported with ipilimumab at both 3 mg/kg and 
10 mg/kg. Visceral and even neurosarcoid findings have 
been noted [68,69]. If new lymphadenopathy is docu-
mented in an otherwise well and responding patient, a 
tissue diagnosis should be obtained to avoid unnecessary 
antineoplastic treatment. Treatment with steroids 
(prednisolone 1∼2 mg/kg) may be required, as in the case 
of symptomatic neuro-sarcoidosis. In an asymptomatic 
patient, observation may be appropriate [70].
CONCLUSION
Although immune-checkpoint inhibitors have im-
proved survival for a range of cancer types, they are com-
monly associated with various types of irAEs. Some irAEs 
are severe and sometimes fatal. However, they are usually 
reversible if recognized early and promptly and properly 
managed. Management algorithms for irAEs have been 
developed and provide a framework within which in-
dividual clinicians may exercise their discretion. Thoughtful 
management of short and medium-term irAEs is im-
portant in optimizing quality of life and long-term 
outcomes. 
Prospective management strategy trials are lacking in 
this field and are required to advance knowledge. 
Therefore, where possible, histological or serological 
confirmation would be helpful to enlighten the nature of 
the autoimmune process, since this may differ. For exam-
ple, hyperthyroidism may be mediated by thyroiditis or 
Grave’s disease, and this can impact the management. 
One challenge lies in deciding when to instigate next-line 
immunosuppression after steroids. Given the potential 
for fatal perforation in those with colitis, we advocate the 
use of infliximab sooner rather than later. These need to 
incorporate prolonged durations of follow-up to identify 
possible late complications. 
Lastly, the field must establish true contraindications to 
use second-line ICPI when the first has been complicated 
by severe irAEs, or whether patients experiencing grade 3 
or 4 toxicity were included in the re-treated cohorts. 
While most clinical trials of ICPIs after first-line treat-
ment excluded patients who had a prior grade 3/4 toxicity 
and mandated a minimum 4-week rest between different 
agents, the practice outside of trials differs under the dis-
cretion of the physicians. Moreover, the best way is an in-
formed discussion with the patient regarding the risk ver-
sus benefit of rechallenge with an ICPI in the context of 
prior severe irAEs, especially when balanced with the 
chance of death from metastatic disease. Patients may al-
so be prepared to accept greater toxicity than that pre-
dicted by their physicians for a relatively small perceived 
benefit.
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